• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertising

New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertising

February 22, 2011
CenterWatch Staff

When an investigative site does not have enough potential subjects within its own patient base for a particular trial it has taken on, one of the tasks it faces is placing ads in local media outlets.

Traditionally, this has involved producing with the ad or hiring talent to do so, obtaining IRB approval for the messages in the ad, determining in which newspaper, TV and/or radio station the ad should run and at what time of day, and then negotiating with those media outlets—often with less than stellar results. On top of all that, sites have had to shoulder the costs of the media buys, invoicing the sponsor for reimbursement months later.

“It’s a horrible process,” said Jim Kremidas, Quintiles’ VP and global head of patient recruitment. “There’s no consistent branding of the study, there’s all that submitting of invoices for all costs, and it’s so time consuming for the sites. And, let’s face it, some aren’t very good at advertising or negotiating media buys.”

To alleviate this added site burden, Quintiles has launched Quintiles Trial Enrollment Accelerator, a website designed to streamline and make fool-proof the ad-buying process for sites. 

According to Kremidas, it works like this: Sites log in and gain access to already designed and IRB-approved advertisements (print, radio and TV), each of which leaves space for the sites to add their own contact information. They can pick and choose ads as well as the times and places those ads will run in their local media outlets, thus creating a media campaign themselves. A professional media buyer is always available to provide one-on-one feedback about their choices. Or, if they choose, they can let the media planner do all the work.

The invoicing process is eliminated, which is a relief for sites financially, said Kremidas, adding that with a professional media buyer negotiating the buys rather than the sites, Quintiles also saves money.

Making it easier for sites financially is key, said Tracy Blumenfeld, co-founder, president and chief executive of RapidTrials, which sets up infrastructure for sites and helps train them. Plus, it could elevate the quality of the advertising.

“Sites will sometimes under-optimize their selection for media because of cash flow issues,” she said. “True, they may not know what the best media buy is due to lack of expertise, but even if they did know, if the best media buy required them to pay out $5,000 and then wait to get reimbursed—which could take three months—they might pick a $125 print ad in a sub-optimal outlet instead.”

Quintiles ran a pilot of the new site last year for two studies. According to the web site’s media planner, about half of the sites who availed themselves of the technology liked the process of choosing ads to tailor a media plan to their market. Another 40% opted to have the planner handle the whole process for them. The remaining 10% said they wanted to keep doing it themselves, hiring the talent, negotiating the buys and placing the ads, then submitting invoices.

Kremidas said Quintiles plans to use the site for about 10 studies this year.

—Suz Redfearn

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing